Abstract
The Chikungunya virus (CHIKV) belongs to the Alphavirus genus of Togaviridae family and contains a positive-sense single stranded RNA genome. Infection by this virus mainly causes sudden high fever, rashes, headache, and severe joint pain that can last for several months or years. CHIKV, a mosquito-borne arbovirus, is considered a re-emerging pathogen that has become one of the most pressing global health concerns due to a rapid increase in epidemics. Because handling of CHIKV is restricted to Biosafety Level 3 (BSL-3) facilities, the evaluation of prophylactic vaccines or antivirals has been substantially hampered. In this study, we first iden-tified the whole structural polyprotein sequence of a CHIKV strain isolated in South Korea (KNIH/2009/77). Phylogenetic analysis showed that this sequence clustered within the East/ Central/South African CHIKV genotype. Using this sequence information, we constructed a CHIKV-pseudotyped lenti-virus expressing the structural polyprotein of the Korean CHIKV isolate (CHIKVpseudo) and dual reporter genes of green fluorescence protein and luciferase. We then developed a pseudovirus-based neutralization assay (PBNA) using CHIKVpseudo. Results from this assay compared to those from the conventional plaque reduction neutralization test showed that our PBNA was a reliable and rapid method to evaluate the efficacy of neutralizing antibodies. More importantly, the neutralizing activities of human sera from CHIKV-infected individuals were quantitated by PBNA using CHIKVpseudo. Taken together, these results suggest that our PBNA for CHIKV may serve as a useful and safe method for testing the neutralizing activity of antibodies against CHIKV in BSL-2 facilities.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Azami, N.A.M., Moi, M.L., and Takasaki, T. 2016. Neutralization assay for chikungunya virus infection: plaque reduction neutralization test. In Chikungunya Virus, pp. 273–282. Springer.
Brehin, A.C., Rubrecht, L., Navarro-Sanchez, M.E., Marechal, V., Frenkiel, M.P., Lapalud, P., Laune, D, and Despres, P. 2008. Production and characterization of mouse monoclonal antibodies reactive to Chikungunya envelope E2 glycoprotein. Virology371, 185–195.
Carleton, M., Lee, H., Mulvey, M, and Brown, D.T. 1997. Role of glycoprotein PE2 in formation and maturation of the Sindbis virus spike. J. Virol. 71, 1558–1566.
Cha, G.W., Cho, J.E., Lee, E.J., Ju, Y.R., Han, M.G., Park, C, and Jeong, Y.E. 2013. Travel-associated Chikungunya cases in South Korea during 2009-2010. Osong Public Health Res. Perspect. 4, 170–175.
Chang, K.S., Kim, G.-H., Ha, Y.R., Jeong, E.J.C., Kim, H.C., Klein, T.A., Shin, S.H., Kim, E.J., Jegal, S., Chung, S.J.,et al. 2018. Monitoring and Control of Aedes albopictus, a Vector of Zika Virus, Near Residences of Imported Zika Virus Patients during 2016 in South Korea. Am. J. Med. Hyg. 98, 166–172.
Fukumoto, Y., Obata, Y., Ishibashi, K., Tamura, N., Kikuchi, I., Aoy-ama, K., Hattori, Y., Tsuda, K., Nakayama, Y., and Yamaguchi, N. 2010. Cost-effective gene transfection by DNA compaction at pH 4.0 using acidified, long shelf-life polyethylenimine. Cytotechnology62, 73–82.
Glasker, S., Lulla, A., Lulla, V., Couderc, T., Drexler, J.F., Liljestrom, P., Lecuit, M., Drosten, C., Merits, A, and Kiimmerer, B.M. 2013. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout. Virol. J.10, 235.
Hu, D., Zhang, J., Wang, H., Liu, S., Yu, L., Sun, L, and Qu, Y. 2014. Chikungunya virus glycoproteins pseudotype with lentiviral vectors and reveal a broad spectrum of cellular tropism. PLoS One9, e110893.
Hwang, J.H. and Lee, C.S. 2015. The first imported case infected with chikungunya virus in Korea. Infect. Chemother. 47, 55–59.
Jain, M., Rai, S, and Chakravarti, A. 2008. Chikungunya: a review. Trop. Doct. 38, 70–72.
Jose, J., Snyder, J.E., and Kuhn, R.J. 2009. A structural and functional perspective of alphavirus replication and assembly. Put. Microbiol. 4, 837–856.
Kishishita, N., Takeda, N., Anuegoonpipat, A, and Anantapreecha, S. 2013. Development of a pseudotyped lentiviral vector-based neutralization assay for chikungunya virus infection. J. Clin. Microbiol. 51, 1385–1395.
Kuo, S.C., Chen, Y.J., Wang, Y.M., Tsui, P.Y., Kuo, M.D., Wu, T.Y., and Lo, S.J. 2012. Cell-based analysis of Chikungunya virus El protein in membrane fusion. J. Biomed. Sci.19, 44.
Lee, H.J., Min, K.I., Park, K.H., Choi, H.J., Kim, M.K., Ahn, C.Y., Hong, Y.J., and Kim, Y.B. 2014. Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test. J. Microbiol. 52, 435–440.
Li, L., Jose, J., Xiang, Y., Kuhn, R.J., and Rossmann, M.G. 2010. Structural changes of envelope proteins during alphavirus fusion. Nature468, 705.
Morrison, T.E. 2014. Re-emergence of chikungunya virus. J. Virol. 88, 11644–11647.
Mulvey, M. and Brown, D.T. 1995. Involvement of the molecular chaperone BiP in maturation of Sindbis virus envelope glycoproteins. J. Virol. 69, 1621–1627.
Noranate, N., Takeda, N., Chetanachan, P., Sittisaman, P., Anuegoonpipat, A, and Anantapreecha, S. 2014. Characterization of chikungunya virus-like particles. PLoS One9, e108169.
Pal, P., Dowd, K.A., Brien, J.D., Edeling, M.A., Gorlatov, S., Johnson, S., Lee, I., Akahata, W., Nabel, G.J., Richter, M.K.,et al. 2013. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog.9, e1003312.
Powers, A.M. 2018. Vaccine and therapeutic options to control chikungunya virus. Clin. Microbiol. Rev.31, e00104–16.
Powers, A.M., Brault, A.C., Tesh, R.B., and Weaver, S.C. 2000. Re-emergence of Chikungunya and O’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81, 471–479.
Rezza, G., Nicoletti, L., Angelini, R., Romi, R., Finarelli, A.C., Panning, M., Cordioli, P., Fortuna, C., Boros, S., Magurano, F.,et al. 2007. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet370, 1840–1846.
Salvador, B., Zhou, Y., Michault, A., Muench, M.O., and Simmons, G. 2009. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in El glycoprotein. Virology393, 33–41.
Sam, I.C., Loong, S.K, Michael, J.C., Chua, C.L., Sulaiman, W.Y.W., Vythilingam, I., Chan, S.Y., Chiam, C.W., Yeong, Y.S., and Abu-Bakar, S. 2012. Genotypic and phenotypic characterization of Chikungunya virus of different genotypes from Malaysia. PLoS One7, e50476.
Schwartz, O. and Albert, M.L. 2010. Biology and pathogenesis of chikungunya virus. Nat. Rev. Microbiol.8, 491.
Snyder, A.J. and Mukhopadhyay, S. 2012. The alphavirus E3 glycoprotein functions in a clade-specific manner. J. Virol. 86, 13609–13620.
Solignat, M., Gay, B., Higgs, S., Briant, L, and Devaux, C. 2009. Replication cycle of chikungunya: a re-emerging arbovirus. Virology393, 183–197.
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M, and Kumar, S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731–2739.
Tharmarajah, K., Mahalingam, S, and Zaid, A. 2017. Chikungunya: vaccines and therapeutics. F1000Res.6, 2114
Thiboutot, M.M., Kannan, S., Kawalekar, O.U., Shedlock, D.J., Khan, A.S., Sarangan, G., Srikanth, P., Weiner, D.B., and Muthumani, K. 2010. Chikungunya: a potentially emerging epidemic? PLoS Negl. Trop. Dis.4, e623.
Volk, S.M., Chen, R., Tsetsarkin, K.A., Adams, A.P., Garcia, T.I., Sail, A.A., Nasar, F., Schuh, A.J., Holmes, E.C., Higgs, S.,et al. 2010. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J. Virol. 84, 6497–6504.
Voss, J.E., Vaney, M.C., Duquerroy, S., Vonrhein, C., Girard-Blanc, C., Crublet, E., Thompson, A., Bricogne, G, and Rey, F.A. 2010. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature468, 709–712.
Weaver, S.C, Osorio, J.E., Livengood, J.A., Chen, R, and Stinchcomb, D.T. 2012. Chikungunya virus and prospects for a vaccine. Expert. Rev. Vaccines11, 1087–1101.
Wichit, S., Hamel, R., Bernard, E., Talignani, L., Diop, F., Ferraris, P., Liegeois, F., Ekchariyawat, P., Luplertlop, N, and Surasombatpattana, P. 2017. Imipramine inhibits Chikungunya virus replication in human skin fibroblasts through interference with intracellular cholesterol trafficking. Sci. Rep.7, 3145.
Wu, J., Zhao, C., Liu, Q., Huang, W, and Wang, Y. 2017. Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system. Vaccine35, 6387–6394.
Yap, M.L, Klose, T., Urakami, A., Hasan, S.S., Akahata, W, and Rossmann, M.G. 2017. Structural studies of Chikungunya virus maturation. Proc. Natl. Acad. Sci. USA114, 13703–13707.
Yeom, J.S. 2017. Current status and outlook of mosquito-borne diseases in Korea. J. Korean Med. Assoc. 60, 468–474.
Acknowledgments
This research was supported by a grant (16172MFDS272) from the Ministry of Food and Drug Safety in 2016-2018, the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1A2B6001363), and a grant from Korea Ministry of Health and Welfare (HI15C2971). The CHIKV strain isolated in Korea (KNIH/2009/77) was obtained from the National Culture Collection for Pathogens, Republic of Korea. The Luc2P-pLVX-IRES-ZsGreenl plasmid for CHIKVpseudo was a kind gift from Dr. Nam-Hyuk Cho at Seoul National University, Republic of Korea. Human serum samples used in this paper were originally collected as part of the Dengue Vaccine Initiative (DVI) study conducted in Ouagadougou, Burkina Faso, by Centre MURAZ and AGIR.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chung, WC., Hwang, K.Y., Kang, SJ. et al. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate. J Microbiol. 58, 46–53 (2020). https://doi.org/10.1007/s12275-020-9384-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-020-9384-0